Gastrointestinal Stromal Tumors II: Medical Oncology and Tumor Response Assessment

Seminars in Oncology

Volumn 36, Issue 4, 2009, Pages 302-311

  Benjamin, Robert S ^a   Debiec Rychter, Maria ^b   Le Cesne, Axel ^c   Sleijfer, Stefan ^d   Demetri, George D ^e   Joensuu, Heikki ^f   Schöffski, Patrick ^g   Poveda, Andrés ^h  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c INSTITUT GUSTAVE ROUSSY   (France)

^d ERASMUS MEDICAL CENTER   (Netherlands)

^e DANA FARBER CANCER INSTITUTE   (United States)

^f HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

AB 1010; ANTINEOPLASTIC AGENT; CONTRAST MEDIUM; CPG 74588; DASATINIB; FLUORODEOXYGLUCOSE F 18; HYPERICUM PERFORATUM EXTRACT; IMATINIB; KETOCONAZOLE; MASITINIB; MIDOSTAURIN; MOTESANIB; NILOTINIB; OSI 930; PAZOPANIB; PROTEIN TYROSINE KINASE INHIBITOR; RIFAMPICIN; SORAFENIB; STEM CELL FACTOR; SUNITINIB; UNCLASSIFIED DRUG; VATALANIB; XL 820;

ARTICLE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER RESISTANCE; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIVITY; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; HUMAN; MEDICAL ASSESSMENT; METASTASIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SARCOMA; TREATMENT OUTCOME; TREATMENT RESPONSE;

DRUG RESISTANCE, NEOPLASM; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MUTATION; PIPERAZINES; PROTO-ONCOGENE PROTEINS C-KIT; PYRIMIDINES; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA;

EID: 68049135508     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.06.003     Document Type: Article

References (61)

1. Karnofsky D.A. Meaningful clinical classification of therapeutic responses to anticancer drugs. Clin Pharmacol Ther 2 (1961) 709-712
2. Miller A.B., Hoogstraten B., Staquet M., and Winkler A. Reporting results of cancer treatment. Cancer 47 (1981) 207-214
3. World Health Organization. WHO handbook for reporting results of cancer treatment. Offset publication No. 48 (1979), World Health Organization, Geneva
4. Moertel C.G., and Hanley J.A. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer 38 (1976) 388-394
5. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
6. Freireich E.J. Who took the clinical out of clinical research?. -Mouse versus man: seventh David A Karnofsky Memorial Lecture-1976. Clin Cancer Res 3 (1997) 2711-2722
7. Van den Abbeele A.D., and Badawi R.D. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 38 Suppl 5 (2002) S60-S65
8. Benjamin R.S., Choi H., Macapinlac H.A., Burgess M.A., Patel S.R., Chen L.L., et al. We should desist using RECIST, at least in GIST. J Clin Oncol 25 (2007) 1760-1764
9. Choi H., Charnsangavej C., Faria S.C., Macapinlac H.A., Burgess M.A., Patel S.R., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 25 (2007) 1753-1759
10. Blanke C.D., Demetri G.D., von Mehren M., Heinrich M.C., Eisenberg B., Fletcher J.A., et al. Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT. J Clin Oncol 26 (2008) 620-625
11. Eisenhauer E.A., Therasse P., Bogaerts J., Schwartz L.H., Sargent D., Ford R., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45 (2009) 228-247
12. Debiec-Rychter M., Dumez H., Judson I., Wasag B., Verweij J., Brown M., et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 40 (2004) 689-695
13. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299 (2003) 708-710
14. Corless C.L., Schroeder A., Griffith D., Town A., McGreevey L., Harrell P., et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol 23 (2005) 5357-5364
15. Dewaele B., Wasag B., Cools J., Sciot R., Prenen H., Vandenberghe P., et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 14 (2008) 5749-5758
16. Debiec-Rychter M., Cools J., Dumez H., Sciot R., Stul M., Mentens N., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 128 (2005) 270-279
17. Janeway K.A., Matthews D.C., Butrynski J.E., D'Amato G.Z., Agresta S., Garrett C., et al. Sunitinib treatment of pediatric metastatic GIST after failure of imatinib [abstract]. J Clin Oncol 24 (2006) 9519
18. Antonescu C.R., Besmer P., Guo T., Arkun K., Hom G., Koryotowski B., et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 11 (2005) 4182-4190
19. Heinrich M.C., Corless C.L., Blanke C.D., Demetri G.D., Joensuu H., Roberts P.J., et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 24 (2006) 4764-4774
20. Wardelmann E., Thomas N., Merkelbach-Bruse S., Pauls K., Speidel N., Buttner R., et al. Acquired resistance to imatinib in gastrointestinal stromal tumours caused by multiple KIT mutations. Lancet Oncol 6 (2005) 249-251
21. Guo T., Agaram N.P., Wong G.C., Hom G., D'Adamo D., Maki R.G., et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 13 (2007) 4874-4881
22. Prenen H., Cools J., Mentens N., Folens C., Sciot R., Schoffski P., et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 12 (2006) 2622-2627
23. Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Harlow A., Griffith D., et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol 26 (2008) 5352-5359
24. Heinrich M.C., Maki R.G., Corless C.L., Antonescu C.R., Fletcher J.A., Fletcher C.D., et al. Sunitinib response in imatinib-resistant GIST correlates with KIT and PDGFRA mutation status [abstract]. J Clin Oncol 24 (2006) 9502
25. Joensuu H., Roberts P.J., Sarlomo-Rikala M., Andersson L.C., Tervahartiala P., Tuveson D., et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 344 (2001) 1052-1056
26. Blanke C.D., Rankin C., Demetri G.D., Ryan C.W., von Mehren M., Benjamin R.S., et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26 (2008) 626-632
27. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347 (2002) 472-480
28. van Oosterom A.T., Judson I., Verweij J., Stroobants S., Donato di Paola E., Dimitrijevic S., et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358 (2001) 1421-1423
29. Verweij J., Casali P.G., Zalcberg J., LeCesne A., Reichardt P., Blay J.Y., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 364 (2004) 1127-1134
30. Verweij J., van Oosterom A., Blay J.Y., Judson I., Rodenhuis S., van der Graaf W., et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 39 (2003) 2006-2011
31. Van Glabbeke M.M., Owzar K., Rankin C., Simes J., and Crowley J. Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): a meta-analyis based on 1,640 patients [abstract]. J Clin Oncol (2007) 25
32. von Mehren M., Wang Y., Joensuu H., Blanke C.D., Wehrle E., and Demetri G.D. Imatinib pharmacokinetics and its correlation with clinical response in patients with unresectable/metastatic gastrointestinal stromal tumor [abstract]. J Clin Oncol 26 (2008) 4523
33. Larson R.A., Druker B.J., Guilhot F., O'Brien S.G., Riviere G.J., Krahnke T., et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 111 (2008) 4022-4028
34. Forrest D.L., Trainor S., Brinkman R.R., Barnett M.J., Hogge D.E., Nevill T.J., et al. Cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia are correlated with Sokal risk scores and duration of therapy but not trough imatinib plasma levels. Leuk Res 33 (2009) 271-275
35. Zalcberg J.R., Verweij J., Casali P.G., Le Cesne A., Reichardt P., Blay J.Y., et al. Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41 (2005) 1751-1757
36. Blay J.Y., Le Cesne A., Ray-Coquard I., Bui B., Duffaud F., Delbaldo C., et al. Prospective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma Group. J Clin Oncol 25 (2007) 1107-1113
37. Le Cesne A., Ray-Coquard I., Bui B., Rios M., Adenis A., Bertucci F., et al. Continuous versus interruption of imatinib in responding patients with advanced GIST after three years of treatment: a prospective randomized phase III trial of the French Sarcoma Group [abstract]. J Clin Oncol 25 (2007) 10005
38. DeMatteo R.P., Maki R.G., Singer S., Gonen M., Brennan M.F., and Antonescu C.R. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor. Ann Surg 245 (2007) 347-352
39. Gronchi A., Fiore M., Miselli F., Lagonigro M.S., Coco P., Messina A., et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245 (2007) 341-346
40. Raut C.P., Posner M., Desai J., Morgan J.A., George S., Zahrieh D., et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 24 (2006) 2325-2331
41. Rutkowski P., Nowecki Z., Nyckowski P., Dziewirski W., Grzesiakowska U., Nasierowska-Guttmejer A., et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 93 (2006) 304-311
42. Peng B., Lloyd P., and Schran H. Clinical pharmacokinetics of imatinib. Clin Pharmacokinet 44 (2005) 879-894
43. Burger H., van Tol H., Brok M., Wiemer E.A., de Bruijn E.A., Guetens G., et al. Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther 4 (2005) 747-752
44. Delbaldo C., Chatelut E., Re M., Deroussent A., Seronie-Vivien S., Jambu A., et al. Pharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumors. Clin Cancer Res 12 (2006) 6073-6078
45. Prenen H., Guetens G., De Boeck G., Highley M., van Oosterom A.T., and de Bruijn E.A. Everolimus alters imatinib blood partition in favour of the erythrocyte. J Pharm Pharmacol 58 (2006) 1063-1066
46. Ramanathan R.K., Egorin M.J., Takimoto C.H., Remick S.C., Doroshow J.H., LoRusso P.A., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26 (2008) 563-569
47. Gibbons J., Egorin M.J., Ramanathan R.K., Fu P., Mulkerin D.L., Shibata S., et al. Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of renal dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol 26 (2008) 570-576
48. Gardner E.R., Burger H., van Schaik R.H., van Oosterom A.T., de Bruijn E.A., Guetens G., et al. Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib. Clin Pharmacol Ther 80 (2006) 192-201
49. de Kogel C.E., and Schellens J.H. Imatinib. Oncologist 12 (2007) 1390-1394
50. van Erp N.P., Gelderblom H., Karlsson M.O., Li J., Zhao M., Ouwerkerk J., et al. Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib. Clin Cancer Res 13 (2007) 7394-7400
51. Judson I., Ma P., Peng B., Verweij J., Racine A., di Paola E.D., et al. Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma Group. Cancer Chemother Pharmacol 55 (2005) 379-386
52. Yuzawa S., Opatowsky Y., Zhang Z., Mandiyan V., Lax I., and Schlessinger J. Structural basis for activation of the receptor tyrosine kinase KIT by stem cell factor. Cell 130 (2007) 323-334
53. Liegl B., Kepten I., Le C., Zhu M., Demetri G.D., Heinrich M.C., et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol 216 (2008) 64-74
54. Taldone T., Gozman A., Maharaj R., and Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 8 (2008) 370-374
55. Wagner A.J., Morgan J.A., Chugh R., Rosen L.S., George S., Gordon M.S., et al. Results from phase 1 trial of IPI-504, a novel HSP90 inhibitor, in tyrosine kinase inhibitor-resistant GIST and other sarcomas [abstract]. J Clin Oncol 26 (2008) 10503
56. Prakash S., Sarran L., Socci N., DeMatteo R.P., Eisenstat J., Greco A.M., et al. Gastrointestinal stromal tumors in children and young adults: a clinicopathologic, molecular, and genomic study of 15 cases and review of the literature. J Pediatr Hematol Oncol 27 (2005) 179-187
57. Tarn C., Rink L., Merkel E., Flieder D., Pathak H., Koumbi D., et al. Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors. Proc Natl Acad Sci U S A 105 (2008) 8387-8392
58. Bui B.N., Blay J., Duffaud F., Hermine O., Hermine O., and Le Cesne A. Preliminary efficacy and safety results of Masitinib administered front line in patients with advanced GIST. A phase II study [abstract]. J Clin Oncol 25 (2007) 10025
59. Joensuu H., De Braud F., Coco P., De Pas T., Putzu C., Spreafico C., et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 19 (2008) 173-177
60. Von Mehren M., Reichardt P., Casali P.G., Blay J., Debiec-Rychter M., Dumez H., et al. A phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors-study update [abstract]. J Clin Oncol 25 (2007) 10023
61. Wiebe L., Kasza K.E., Maki R.G., D'Adamo D.R., Chow W.A., Wade J.L., et al. Activity of sorafenib in patients with imatinib and sunitinib-resistant gastrointestinal stromal tumors: a phase II trial of the University of Chicago Phase II Consortium [abstract]. J Clin Oncol 26 (2008) 10502